About Aurore Life Sciences Private Limited
Data last updated:
Aurore Life Sciences Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Hydra Active Pharma Sciences Private Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 26 September 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U74999MH2016PTC371990. Its GSTIN is 36AAOCA7876R1ZG (Telangana).
The company has an authorised share capital of ₹174 Cr and a paid-up capital of ₹116.58 Cr. It is led by directors including Rajender Juvvadi Rao (Managing Director) and Pudhucode Radhakrishnan Kannan.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at First Floor Fine Mansion 203 D.N. Road Fort, Mumbai, Maharashtra, India – 400001.
As per the financials filed for FY 2025, the company reported a revenue of ₹471.23 Cr, a growth of 5% compared to the previous year. For the same year it recorded a net loss of ₹34.02 Cr (net margin -7.2%) and EBITDA of ₹55.5 Cr (EBITDA margin 11.8%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years and 18% over five years.
The company has about 437 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand: Aurore Life Sciences. As per MCA filings, the company has open charges of ₹953.13 Cr on record. Court records list 24 cases involving the company, including 4 filed by the company and 20 filed against it; 12 cases are pending. The company has 12 deals on record (4 rights issues, 2 funding rounds, 2 debt financings), with disclosed funding of ₹548.11 Cr; the latest was in October 2024. Its 5 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 3 smaller; the largest is Arene Life Sciences Private Limited with revenue of ₹497.82 Cr. The company has 16 MSME Form 1 returns on record between 2019 and 2023, listing 1,459 overdue payments to 178 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurorels.com.
Company details
CIN history
Aurore Life Sciences has one previous CIN (Corporate Identification Number): U74999TG2016PTC112170. The current CIN is U74999MH2016PTC371990, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U74999MH2016PTC371990 | Current |
| U74999TG2016PTC112170 | Previous |
Contact details
Aurore Life Sciences Private Limited's registered office is in Mumbai, Maharashtra. Its website is aurorels.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressFirst Floor Fine Mansion 203 D.N. Road Fort, Mumbai, Maharashtra, India – 400001
- IndustryPharma, API Manufacturers
To see the full contact details of Aurore Life Sciences Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Aurore Life Sciences operates one associated brand: Aurore Life Sciences. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Develops and produces Active Pharmaceutical Ingredients and intermediates for pharmaceutical markets. | aurorels.com |
Business activity
The main business activity of Aurore Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Aurore Life Sciences Private Limited, buy the company report.
Financials of Aurore Life Sciences Private Limited
FY 2024 filings availableAurore Life Sciences Private Limited reported revenue of ₹471.23 Cr (up 5% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 18% over five years, including 5% growth in the latest year. EBITDA fell 10% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹55.5 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹34.02 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 11.8% | ||||
| Net Profit Margin | -7.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Aurore Life Sciences Private Limited, buy the company report.
Board of directors of Aurore Life Sciences Private Limited
Aurore Life Sciences has 4 current directors and 13 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajender Juvvadi Rao Also directs: Aurore Healthcare Private Limited | Managing Director | 15 Jun 2017 | 9 Years 4 Months | Current |
| Pudhucode Radhakrishnan Kannan Also directs: Dvise Medtech Private Limited, Serovia Pharma Private Limited, Dvise Pharma Tech Private Limited and 4 more | Additional Director | 13 Jan 2025 | 1 Years 9 Months | Current |
| Dilip Murthy Buddha Also directs: Meraki Synergies LLP | Nominee Director | 01 Oct 2025 | 1 Years 0 Months | Current |
| Suresh Mudhunuri | Nominee Director | 01 Oct 2025 | 1 Years 0 Months | Current |
Peer comparison
Aurore Life Sciences Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Arene Life Sciences Private Limited | ₹497.82 Cr (FY 2025) | 23.0% | Sangareddy, Telangana, India | |||
| Aarey Drugs and Pharmaceuticals Limited | ₹483.76 Cr (FY 2025) | 20.0% | Thane, Maharashtra, India | |||
| Aurore Life Sciences Private Limitedthis company | ₹471.23 Cr (FY 2025) | -₹34.02 Cr | -7.2% | 5.0% | 437 | Mumbai, Maharashtra, India |
| CTX Lifesciences Private Limited | ₹464.3 Cr (FY 2025) | 24.0% | Surat, Gujarat, India | |||
| Biophore India Pharmaceuticals Private Limited | ₹457 Cr (FY 2025) | 18.0% | Hyderabad, Telangana, India | |||
| S Kant Healthcare Limited | ₹452.24 Cr (FY 2025) | -1.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Aurore Life Sciences Private Limited, buy the company report.
Auditor
Aurore Life Sciences Private Limited is audited by Laxminiwas&Co for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Laxminiwas&Co | FY 2023 | 011168S |
Shareholding
The shareholding of Aurore Life Sciences Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Aurore Life Sciences Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 28 Jun 2025 | 101122297 | Others | ₹50 Cr | Open | |
| 25 Apr 2025 | 101089850 | Yes Bank Limited | ₹50 Cr | Open | |
| 27 Sep 2024 | 100997729 | Others | ₹300 Cr | Open | |
| 28 Feb 2023 | 100698030 | Tata Capital Financial Services Limited | ₹60 Cr | Open | |
| 09 Dec 2022 | 100660442 | Others | ₹18 Cr | Open |
To see the full charge records of Aurore Life Sciences Private Limited, buy the company report.
Total charge records: 16 View all charges
Deals & funding
Aurore Life Sciences Private Limited has 12 deals on record (4 rights issues, 2 funding rounds, 2 debt financings), with disclosed funding of ₹548.11 Cr; the latest was in October 2024.
Deals on record (5 of 12)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2024 | Debt financing | ₹210 Cr | Investors: Modulus Alternatives, Centrum Capital Advisors Limited |
| Jan 2024 | Debt financing | ₹50 Cr | Investors: Kemfin Services Private Limited , Culture Carousel LLP |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Hydra Active Pharma Sciences Private Limited , an individual |
| Jan 2021 | Rights issue | ₹20.03 Cr | Investors: Hydra Active Pharma Sciences Private Limited , an individual |
| Mar 2019 | Rights issue | ₹12.79 Cr | Investors: Hydra Active Pharma Sciences Private Limited |
To see the full deal history of Aurore Life Sciences Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Aurore Life Sciences Private Limited has 24 court cases on record: 4 filed by Aurore Life Sciences, 20 filed against it. 12 cases are pending and 12 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 18 | 18 | 8 |
| NCLAT | 4 | 0 | 3 |
| High courts | 1 | 1 | 1 |
| NCLT | 1 | 1 | 0 |
Cases on record (5 of 24)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary Cases) | Filed against the company by Deep Pharm Chem Private Limited Through Its Authorized Representative Mr Navin Amarshi Hansora | Pending |
| District court, Sangareddy, Telangana | Cheque dishonour complaint | Filed against the company by Arene Life Sciences Private Limited | Pending |
| NCLAT, Court III | Tribunal matter | Filed by the company against Tenshi Life Sciences Private Limited and 10 others | Pending |
| NCLAT, NCLAT New Delhi | Interim or miscellaneous application | Filed by the company against Aurore Pharmaceuticals Private Ltd. and 11 others | Pending |
| District court, Chennai, Tamil Nadu | Court case (PC) | Filed against the company by M/S. Pon Pure Chemical India Private Limited Rep by Mr Jino Antony, Chief Manager-Legal | Disposed |
To see the full case history of Aurore Life Sciences Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Aurore Life Sciences Private Limited was last rated by Icra on 09 Jun 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 09 Jun 2022 |
To see the full credit ratings and regulatory alerts of Aurore Life Sciences Private Limited, buy the company report.
MSME payment delays
Aurore Life Sciences Private Limited has 16 MSME Form 1 returns on record between 2019 and 2023, listing 1,459 overdue payments to 178 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 178)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Vision Drugs Private Limited | |||
| Sun Life Sciences | |||
| Greentech Hvac Engineers | |||
| Reliability Engineering Industries Private Limited | |||
| Savant Enterprises |
To see the full MSME payment records of Aurore Life Sciences Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Aurore Life Sciences has 2 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Empyrean Lifesciences Private Limited | U24232MH2014PTC367624 | |
| Aurore Pharmaceuticals Private Limited | U24239TG2017PTC117032 |
To see the full group structure of Aurore Life Sciences Private Limited, buy the company report.
Employees & EPFO
Aurore Life Sciences Private Limited has a workforce of 437 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.
GST
Aurore Life Sciences has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAOCA7876R1ZG | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Aurore Life Sciences Private Limited, buy the company report.
Recent activity
Aurore Life Sciences Private Limited has 16 board changes on record since 2017: 6 appointments and 10 cessations. The latest: Dilip Murthy Buddha was appointed as Nominee Director on 01 Oct 2025.
29 earlier events are in the company report.
Frequently asked questions
Aurore Life Sciences is an active private limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 26 September 2016 (10+ years old) and is registered under CIN U74999MH2016PTC371990.
Aurore Life Sciences has 4 current directors:
- Rajender Juvvadi Rao - Managing Director
- Pudhucode Radhakrishnan Kannan - Additional Director
- Dilip Murthy Buddha - Nominee Director
- Suresh Mudhunuri - Nominee Director
The latest financial statements of Aurore Life Sciences on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Aurore Life Sciences is 36AAOCA7876R1ZG, registered in Telangana.
The CIN (Corporate Identification Number) of Aurore Life Sciences is U74999MH2016PTC371990. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Aurore Life Sciences has 24 court cases on record: 4 filed by the company and 20 filed against it. 12 are pending. Most are in the district courts.
Aurore Life Sciences was incorporated on 26 September 2016, making it 10+ years old. It is registered with the Registrar of Companies, Mumbai.
Aurore Life Sciences has 12 deals on record (4 rights issues, 2 funding rounds, 2 debt financings), with disclosed funding of ₹548.11 Cr; the latest was in October 2024.
The peers of Aurore Life Sciences by revenue are Arene Life Sciences Private Limited, Aarey Drugs and Pharmaceuticals Limited, CTX Lifesciences Private Limited, Biophore India Pharmaceuticals Private Limited, S Kant Healthcare Limited, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Dilip Murthy Buddha was appointed as Nominee Director on 01 Oct 2025. Suresh Mudhunuri was appointed as Nominee Director on 01 Oct 2025. Pudhucode Radhakrishnan Kannan was appointed as Additional Director on 13 Jan 2025. Aurore Life Sciences has 16 board changes on record in total.
Aurore Life Sciences has 16 MSME Form 1 returns on record between 2019 and 2023, listing 1,459 overdue payments to 178 micro and small suppliers. The latest return was filed on 30 Aug 2023.
Aurore Life Sciences can be reached through the website aurorels.com. Its registered office is in Mumbai, Maharashtra, India.